Low Dose Quinine For Treatment Of Chloroquine Resistant Falciparum Malaria by Hamid, Mohamed
                                                     
 
University of Khartoum 
Graduate College 
                  Medical & Health Studies Board 
 
 
 Low   Dose     Quinine  For Treatment   Of  Chloroquine  
Resistant  Falciparum  Malaria. 
 
By                                                           
Mohamed Hamid  Ahmed                                         
 M.B.B.S(Alarab Medical University) 1992  
 
                                                              
AThesis submitted in partial fulfillment for the requirements 
of   the  degree of Clinical MD in Medicine, October 2005 
       
Supervior 
Professor Musa Mohamed Kheir 
MD 
 
Professor of Medicine 
U of K 
 
 I
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I  dedicate  this   thesis  to  my   brother  Nour  Eldin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 II
 
 
 
       
        In  preparation  of  this   thesis    I  have  received   assistance  from  
many  sources, and  I am  deeply  grateful  to  all  those  who  supported  
me 
        I am  especially  indebted  to  Dr.  Musa  Mohamed  Kheir  for  his  
intellectual  support  and  guidance. 
        I am  also  indebted  to  Dr. Ishag  Adam  Ahmed  for  his  unlimited  
intellectual  support,  encouragement  and  patience.           
        I  thank  the  staff  of  Elhara  Eloula  Health  Center  for  their  
invaluable  assistance. I  also  thank  Dr. Elrashid, Dr. Walid, Dr. 
Elmughira and  Dr.  Amre  for  their  continuous  support  and  excellent  
assistance.  
         I  would  like  to  express  my  appreciation  to  Mr.  Abd  Allah  for  
his  excellent  technical  assistance. 
         I  would  like  to  indicate  my   gratefulness  to Dr. Mustafa Idris, 
Head  department  of  biochemistry,  Faculty  Of  Medicine,  University  
Of  Khartoum. 
          I  would  like  to  thank  the  administration  of  Sugar  Cane  
Factory, New  Halfa  for  their  unlimited  support. 
           Lastly, but  not  the  least, I would  like  to  express  my  
gratefulness  to  the  patients; without  their  active  participation  and  
help  this  work  would  not  be  completed. 
           
 
 III
Abstract 
               The  current  recommended  dose  of   10mg quinine/kg  body  
weight  3 times  a day  for 7 days  for  treatment  of  chloroquine  resistant        
falciparum  malaria  is  so  high  that  many  patients    may  suffer  
cinchonism. In  order  to  identify  the  lowest  effective  dose  of  quinine  
for  treatment  of  chloroquine  resistant  malaria, we  enrolled  ninety 
three  patients  who  presented  to  the  health  centre  at  Elhara  Eloula, 
New  halfa, Eastern  Sudan  with  symptoms  of  malaria  after  
completing  the full dose of chloroquine. The  patients  were  randomized  
in  three  treatment  groups  for  quinine  treatment. They   received  
quinine  for  7 days  as  follow: 10mg/kg  thrice daily (group I, 32 
patients), 10mg/kg twice daily (group 2,31 patients)  and 15mg/kg  once  
daily  (group 3,30 patients). All  patients  were  followed  daily  for  7 
days  and  then  weekly  for  3  weeks. There  was  no  significant  
differnce  in  parasite  clearance  time  between  the  three  groups. 
Parasitaemia  was  detected  during  the  follow- up  on  day  28  or  
earlier  in 2/32(6.3%), 5/31(16.1%) and 5/30(16.7%)  in  the  three  
groups, respectively; this  differnce  was  not  significant. In 75%  of    
these  patients  the  parasitaemia  was  due  to  true  recrudescence, as  
confirmed  by  parasite  genotyping . Thus, the  data  in  this  study  
showed  that  low  dose  of  quinine  can  be  prescribed  to  treat  
chloroquine  resistant  falciparum  malaria  in  Sudan  with  comparable  
outcome  to  high  quinine  dose.  
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  ﺑﺴﻢ اﷲ اﻟﺮﺣﻤﻦ اﻟﺮﺣﻴﻢ
                                                          اﻟﺨﻼﺻﺔ
ﻜﺠﻡ ﻤﻥ ﻭﺯﻥ ﺍﻟﺠﺴﻡ ﺜﻼﺜﺔ /ﻤﻠﻐﻡ01ﺇﻥ ﺠﺭﻋﺔ ﺍﻟﻜﻴﻨﻴﻥ ﺍﻟﻤﻭﺼﻰ ﺒﻬﺎ ﺤﺎﻟﻴﺎﹰ ﻭﺍﻟﺒﺎﻟﻐﺔ 
ﻤﺭﺍﺕ ﻴﻭﻤﻴﺎﹰ ﻟﻤﺩﺓ ﺃﺴﺒﻭﻉ ﻟﻤﻌﺎﻟﺠﺔ ﻤﻼﺭﻴﺎ ﺍﻟﻔﺎﻟﺴﻴﺒﺎﺭﻡ ﺍﻟﻤﻘﺎﻭﻤﺔ ﻟﻠﻜﻠﻭﺭﻭﻜﻭﻴﻥ، ﻫﻲ ﺠﺭﻋﺔ ﻜﺒﻴﺭﺓ 
    .ﻥ ﻜﺜﻴﺭ ﻤﻥ ﺍﻟﻤﺭﻀﻰ ﻗﺩ ﻴﻌﺎﻨﻭﻥ ﻤﻥ ﺃﻋﺭﺍﺽ ﺍﻟﺘﺴﻤﻡ ﺒﺎﻟﻜﻴﻨﻴﻥﻟﺩﺭﺠﺔ ﺃ
,  ﻟﻠﻜﻠﻭﺭﻭﻜﻴﻥﻤﻥ ﺃﺠل ﺍﻟﺘﻌﺭﻑ ﻋﻠﻲ ﺃﻗل ﺠﺭﻋﺔ ﻤﻥ ﺍﻟﻜﻴﻨﻴﻥ ﻟﻤﻌﺎﻟﺠﺔ ﺍﻟﻤﻼﺭﻴﺎ ﺍﻟﻤﻘﺎﻭﻤﺔ 
ﻓﻘﺩ  ﻗﻤﻨﺎ  ﺒﺘﻘﺴﻴﻡ  ﺜﻼﺜﺔ  ﻭﺘﺴﻌﻭﻥ  ﻤﺭﻴﻀﺎ  ﻤﻥ  ﺍﻟﺫﻴﻥ  ﺤﻀﺭﻭﺍ  ﻟﻠﻤﺭﻜﺯ  ﺍﻟﺼﺤﻰ ﺒﺎﻟﺤﺎﺭﺓ  
 ﺃﻥ  ﺃﻜﻤﻠﻭﺍ ﺍﻟﻤﺩﺓ  ﺍﻟﻤﻘﺭﺭﺓ ﻟﻠﻌﻼﺝ  ﺒﺎﻟﻜﻠﻭﺭﻭﻜﻭﻴﻥ  ﺸﺭﻕ  ﺍﻟﺴﻭﺩﺍﻥ  ﺒﻌﺩ ,ﺍﻷﻭﻟﻲ  ﺒﺤﻠﻔﺎ  ﺍﻟﺠﺩﻴﺩﺓ 
  .ﺃﻟﻰ  ﺜﻼﺜﺔ  ﻤﺠﻤﻭﻋﺎﺕ  ﻋﺸﻭﺍﺌﻴﺎ  ﻟﻤﻌﺎﻟﺠﺘﻬﻡ  ﺒﺎﻟﻜﻴﻨﻴﻥ
 ﺍﻟﻤﺠﻤﻭﻋﺔ  ﺍﻷﻭﻟﻰ - :ﺠﻤﻴﻊ  ﺍﻟﻤﺭﻀﻰ  ﻋﻭﻟﺠﻭﺍ  ﺒﺎﻟﻜﻴﻨﻴﻥ  ﻟﻤﺩﺓ  ﺃﺴﺒﻭﻉ  ﻜﻤﺎ  ﻴﻠﻰ
, ﻭﺯﻥ  ﺍﻟﺠﺴﻡ  ﺜﻼﺜﺔ  ﻤﺭﺍﺕ  ﻴﻭﻤﻴﺎﻜﺠﻡ  ﻤﻥ  /ﻤﻠﺠﻡ01ﺘﻠﻘﺕ  ﺍﻟﻜﻴﻨﻴﻥ  (  ﻤﺭﻴﻀﺎ23)
 03 )ﻜﺠﻡ  ﻤﺭﺘﻴﻥ  ﻴﻭﻤﻴﺎ  ﻭﺍﻟﻤﺠﻤﻭﻋﺔ  ﺍﻟﺜﺎﻟﺜﺔ/ﻤﻠﺠﻡ01  ﺘﻠﻘﺕ  ( ﻤﺭﻴﻀﺎ13)  ﺍﻟﺜﺎﻨﻴﺔﺍﻟﻤﺠﻤﻭﻋﺔ 
 .ﻜﺠﻡ  ﻤﺭﺓ  ﻭﺍﺤﺩﺓ ﻴﻭﻤﻴﺎ/ﻤﻠﺠﻡ51  ﺘﻠﻘﺕ  (ﻤﺭﻴﻀﺎ
 .  ﺃﺴﺎﺒﻴﻊﺃﺴﺒﻭﻉ  ﺜﻡ  ﺃﺴﺒﻭﻋﻴﺎ  ﻟﻤﺩﺓ   ﺜﻼﺜﺔﺍﻟﻤﺭﻀﻰ  ﺘﻤﺕ  ﻤﺘﺎﺒﻌﺘﻬﻡ  ﻴﻭﻤﻴﺎ  ﻟﻤﺩﺓ  ﻜل 
  ﺍﻟﺩﻡ  ﺒﻴﻥ  ﺍﻟﻤﺠﻤﻭﻋﺎﺕ  ﻫﻨﺎﻙ  ﻓﺭﻕ  ﻓﻰ  ﺯﻤﻥ  ﺍﻟﺘﺨﻠﺹ  ﻤﻥ  ﻁﻔﻴﻠﻰ  ﺍﻟﻤﻼﺭﻴﺎ  ﻤﻥﻟﻴﺱ 
 ﻭﺍﻟﻌﺸﺭﻴﻥ  ﺃﻭ  ﻗﺒﻠﺔ   ﺍﺜﻨﺎﺀ  ﺍﻟﻤﺘﺎﺒﻌﺔ  ﻭﺠﺩﺕ  ﺍﻟﻁﻔﻴﻠﻴﺎﺕ  ﻓﻰ  ﺍﻟﺩﻡ  ﻓﻰ  ﺍﻟﻴﻭﻡ  ﺍﻟﺜﺎﻤﻥ . ﺍﻟﺜﻼﺜﺔ
ﻤﻥ  %(  7.61)5ﺍﻟﻤﺠﻤﻭﻋﺔ  ﺍﻟﺜﺎﻨﻴﺔ  ﻭﻤﻥ %( 5.61)5, ﻤﻥ ﺍﻟﻤﺠﻤﻭﻋﺔ ﺍﻷﻭﻟﻰ%( 3.6)2  ﻓﻰ
ﻤﻥ  ﺘﻠﻙ  %  57 ﻓﻰ  ﻓﻘﺩ  ﺍﺘﻀﺢ  ﺃﻨﺔ , ﺍﻟﺠﻴﻨﻰ  ﻟﻠﻁﻔﻴﻠﻰﺒﻌﺩ ﺍﻟﻔﺤﺹ . ﻤﻭﻋﺔ  ﺍﻟﺜﺎﻟﺜﺔﺍﻟﻤﺠ
  .ﺍﻟﺤﺎﻻﺕ  ﻴﻌﺯﻯ  ﻅﻬﻭﺭ  ﺍﻟﻁﻔﻴﻠﻴﺎﺕ  ﻟﺘﻨﺸﻴﻁ  ﺍﻷﺼﺎﺒﺔ  ﻤﺭﺓ  ﺃﺨﺭﻯ
ﺍﻟﻜﻴﻨﻴﻥ  ﻴﻤﻜﻥ  ﺍﺴﺘﻌﻤﺎﻟﻬﺎ  ﻟﻌﻼﺝ  ﻤﻥ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ ﻴﺘﻀﺢ ﺃﻥ ﺍﻟﺠﺭﻋﺔ ﺍﻟﻤﺨﻔﻀﺔ ﻤﻥ 
ﺍﻟﻤﻼﺭﻴﺎ  ﺍﻟﻤﻘﺎﻭﻤﺔ  ﻟﻠﻜﻠﻭﺭﻭﻜﻭﻴﻥ  ﻓﻰ  ﺍﻟﺴﻭﺩﺍﻥ   ﻤﻊ  ﺍﻋﻁﺎﺀ  ﻨﺘﺎﺌﺞ  ﻤﺸﺎﺒﻬﺔ  ﻟﻠﺠﺭﻋﺎﺕ  
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Introduction & Literature Review 
Malaria: 
In Sudan malaria is a major  health problem accounting for about 
40% of all infectious disease and plasmodium falciparum is the predominant 
species, which is responsible for over 90% of the infection(1). 
One of the essential elements in control of the disease is 
appropriate management and chemotherapy to reduce morbidity and to 
prevent mortality. Unfortunately, falciparum malaria is becoming 
increasingly resistant, in most of the endemic areas world wide, to most 
available drugs including chloroquine  and quinine(2). 
This grave concern was deepened by reality that there is no  
available effective vaccines until now. 
  In order to increase compliance , it would be an advantage to 
reduce the total daily dose and the number of daily doses to minimum. 
We therefore decided to evaluate once daily dose of quinine giving 
15mg/kg/ daily with thrice daily doses giving 10mg/kg/ dose and twice 
daily doses giving 10mg/kg/dose for treatment of chloroquine resistant 
malaria. 
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Malaria and Chloroquine Resistance in Sudan 
Chloroquine  has  been  in  use  for  treatment  of  malaria  in  
Sudan  for  more  than  40  years. The  possible  occurrence  of  
chloroquine  resistant  forms  of  falciparum   malaria  in  Sudan  was  
initially  suggested  in  1978  in  the  Central  Sudan  where  0.4%  and 
o.2%  of  the  patients  were  having  R1  and  R11 resistance,  
respectively (3). Few  years  later, in  Wad  Medani (Central  Sudan), all 
grades  of  chloroquine  resistance  were  reported  in  children,  where  
25%  of  the  parasite  isolates  from  patients  were  chloroquine  
resistant;  8.3%  were  late  R1  and  16.7%  were  RIII(4). 
           In  the  capital  Khartoum  resistanc  to  chloroquine  was  found  
to  be  61.5%; 34.6% as R1  and  26.9%  as  RII (5). Recently, High  level  
of  chloroquine  resistance (75%)  was  seen  among  280  falciparum  
patients  visiting  Omdurman  Hospital(6). This  rapid  increase  in  
resistance  may  be  partially  due  to  social  and  environmental  changes  
occurring  in  the  area (7). 
            In  Eastern  Sudan  the  situation  of  the  chloroquine  resistance  
is  also  serious. It  was  reported    that  42%  of  the  patients  treated  
with  chloroquine  were  resistant, 16% with  severe  RIII  forms  of  
resistance (8). In  New  Halfa (Eastern  Sudan ), among  26 patients  
treated  with  chloroquine, 76.9% were  found  to  be  resistant; 53.8% 
were  early  RI, 7.7%  were  late RI and  15.4%  were R III (9). 
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           From  the  above  data  it  is  clear  that  chloroquine  resistance  is  
spreading  widely  and  rapidly  in  Sudan  reaching  alarming  high  
percentage. 
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History 
The  malaria  parasites that  infect  human  are  species  of  the                          
genus  plasmodium  of  the  class  sporozoa  in  which   the  asexual  
cycle  (Schizogony)  takes  place  in  the  red  blood  cells  of  the  
vertebrate  and the  sexual  cycle  (Sporogony )  in  the  mosquitoes. The 
members  of  this  genus  which  causes  malaria  in  mammals,  have  
close  similarities  in  morphology  and  life  cycles . 
Malaria, paludism, intermittent  fever, chills, Roman  fever, 
charges fever, march  fever, tropical  fever  and  coastal  fever  are  
different    names  given  to  malaria . 
The  term  malaria  is  derived  from  two  different  Italian  words , 
mal (Bad) and  aria  (Air ) . Hippocrate  divided  miasmic  fever  into  
continuous, quartan  and  tertian  fever . 
In  1638, the  countess   El  Cinchona , wife  of  the  vice roy  of  
Peru, was  cured  from  malaria  by  bark  of  certain  trees, later  called  
cinchona , from  which  quinine  was  later  extracted . 
Malaria  spec ies :  
P. Malariae  was  described  in  1880  by Laveran , P.Vivax  was  
named. In  1890  by  Grassi  and  Feletti , P. Falciparum  in  1897  by  
Wechi  and  P. Ovale  in  1922  by  Stephen . In  1898  Ros  published  a 
description  of  sporogony  of the  avian  species  P.Relictum in  culucine  
mosquitoes. 
              Yet  it  was  not  until  1948  that  Short  et al.  demonstrated the 
exoerythrocytic  cycle  of  human  malaria  parasites (10) . 
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Life  cycle :-  
 The life  cycle  of  the  plasmodia  takes  place  in two  hosts, 
vertebrate  and  mosquitoes.  The asexual  cycle  in the  vertebrate  host  
is  known  as  schizogony , and  the sexual  cycle  in the  mosquito  as  
sporogony.  
Schizogony :- 
 The  infectious   sporozoites  from   salivary   glands  of  an  
infected  female   anophline  mosquito  are  injected   during  biting  into  
human  blood  stream  within 30  minutes.  The  slender,   motile   
organism   enters  the  liver  parenchymal  cells  initiating  the  
exoerythrocytic  cycle.  Within  the liver  cells  the  parasite  begins  an  
extensive  multiplication  and  are called  schizonts,  which  produce  
thousands  of  merozoites  8 – 15  days  later  depending  upon the species  
of  the   plasmodia .  The parasitized  liver  cells  eventually  ruptured  
freeing  the  merozoites  in  the  blood  stream  to initiate  the  
erythrocytic  cycle.  Some  schizonts  of  P. vivax  and P. Ovale  may  
remain  in  the liver  cells  (Hypnozoites) which are responsible  for  later  
relapses,  however,  in  P. Falciparum,  in  which  true  relapses  do  not  
occur,  the  hepatic  schizonts  apparently  survive   only  for  short  time.                          
A  relapse  signifies   that   parasitaemia  develops   from  exoerythrocytic  
stage  in  the  liver.  A recrudescence  means  an  increase  in  parasites  
count  that  has  persisted  at  low  level  in the blood. 
 The erythrocytic  cycle  consists  of  invasion  of  red cells  by 
merozoites, their  development  through  trophozoites,  then  schizonts, 
the rupturing  of  the cells  and  re- invasion of  new  cells. As  repeated  
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cycles  of  asexual   multiplication  occur,   some  parasites  which   
invade  red  cells  do not undergo  division   as   schizonts,  but instead  
are  transformed  into  male  and   female  gametocytes.  
Sporogony  :- 
Sporogony, the  sexual  cycle, takes  place  in  the  mosquito.  The 
gametocyte  are  ingested  with the blood  meal, unlike  schizonts, they  
are not digested. The male  is  known  as  microgametocyte  while  the  
female as macrogametocyte. After  maturation, fertilization  will occur 
forming  the  zygote.  Within 12 – 24 hours  after  the  mosquito’s  meal,  
the zygote  changes  into  a  wormlike  form  called  the  ookinete, which  
penetrate  the wall  of  the  mosquito  gut  and develops  into  spherical  
oocyte between the epithelium  and the basement  membrane. Here it 
increases to many times its original  size, with  thousands  of  sporozoites  
developing  inside . After the  rupture  of  oocyte, sporozoites  will enter 
the body  cavity  and  migrate  to salivary  glands. When  the  mosquito 
feeds  on  human, the    sporozoites  gain  access  to  the  blood  and  
tissues  to  begin  exoerythrocytic  cycle . The  sporogony  takes  10–17 
days .Transmission of  malaria  may  occur  by  other  mechanisms  such 
as  blood   transfusion, contaminated  syringes or  across  the placenta (10).
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Epidemiology  of  malaria 
 
             Malaria  remains  the  most  important  of  the  tropical   diseases.            
The  spread is  wide  through  the  tropics,  but  also  occurring  in  many  
temperate  regions.  Each  year  there  are  300 – 500  millions  clinical   
cases   of  malaria. About  40%  of  the  world  population  is  at  risk  of  
acquiring  the  disease. (11) 
P. Flciparum  predominate  in  sub-sahran Africa,  New Guinea   
and   Haiti .While   P.Vivax  is  more  common  in  Central America  and  
the  Indian  sub-continent, an increase in P. Flciparum  has occurred in 
Indian sub-continent  over the past decade. The prevalence of these two 
species is approximately equal in South America and Eastern Asia. P. 
Malaria is found in most areas (Particulary in west and central Africa) but 
is less common. P. Ovale is relatively unusual outside Africa..(12) 
The manifestation of malaria  in people who grow up in endemic 
areas vary with the degree of endemicity, the age of the patient and the 
development of immunity. 
In hypoendemic area little immunity is acquired, epidemics of 
malaria are liable to occur, less than 10% of children have parasitaemia 
and palpable spleen. 
In mesoendemic areas malaria is frequent, but only seasonal , 11-
50% of children have parasitaemia and palpable spleen. Repeated 
infections lead to anaemia and ill health. 
In hyperendemic areas malaria transmission  takes  place all over  
the year, but with  seasonal  increases, 51 - 75% of children have  
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parasitaemia  and palpable  spleen, adult develop occasional short  bouts 
of fever. 
In holoendemic areas malaria  is intense  throughout  the year, 
more than 75%  of children   develop  palpable  spleen and parasitaemia. 
Three characteristics  mainly  determine  the  difference in  
epidemiology of malaria are seen. They are  :- the density, biting habit  
and longevity  of  the  mosquitoes. 
Density  is  the number  of vectors  present  in place  relative  to  
human  population, as might be  expected,  malaria    transmission   will  
tend  to  be  proportional  to  mosquitoes  density.  A mosquito   that  
frequently  bite  will  have  a greater  chance  of  both  picking  up  and 
passing  on  the parasite;  this  factor  has  a  large  effect  on malaria    
transmission.  Once  the  mosquito  became   infected,  it  will  remain   so  
for  her  rest  of  life;  this  longevity  has  greater  influence   on  malaria   
transmission. 
In  Sudan  malaria  is one of  the  most  serious  health  problems,  
accounting  for  some  40 %  of  all infectious   diseases. The predominant   
parasite is p.  falciparum,  which   is  responsible   for  90 %  of all  
reported  malaria  cases ( 1). 
Traditionally  the  southern  part  of  the  country  was  considered  
to  be  holoendemic  with   malaria. The disease  has  spread  across  the 
country  to  many  regions,  previously known  to  be   free  of  the  
disease.   The  fast  spread  of   the disease  has  made   central   Sudan,  
Khartoum   province  and even  the northern   part   holoendemic   with  
malaria (7) . The  reasons  for  the spread  are:-  
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1. Heavy  rains  and  flood  all over  the  country  occurring  in 1988, 
1992, 1994 and  the successive  years. 
2. Deterioration  of  the environmental  health. 
3. Mass migration  of the  refugees,  many  of  whom are  human  
carriers  of  malaria  from  the south  to all  parts  of  the  
country(13). 
Resistance  of the  parasite  to choloroquine  is now well  
documented,  this  was  initially  suggested  in  1978  in  Jazira (3). 
However, later  studies   conducted  at  central  Sudan (5) and  eastern  
Sudan  (8), confirmed  the  presence  of  the  resistance. 
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Pathophysiology 
 
The  spectrum of  the  pathological  process  differs  with  changes  
in  the degree  of  endemicity. In  the  areas  of  high  endemicity, the  
greatest  to  suffer  are  children  less  than  five  years  of  age, whereas  
in  areas  of  low  endemicty, the  disease  affects  all  age  groups.            
 The pathological changes associated with all types of 
 malaria  have  certain  features  in  common, but  the  best  known  are  
those  for  P. Falciparum  malaria. A peculiar  feature  of  P.Falciparum  is  
ability  of  the  parasitized  cells  to  adhere  to venular  endothelium  
(cytoadherence). These  parasitized  cells  remained  attached  until  the  
merozoites  are  formed  and  released  to  invade  other  erythrocytes. 
Thus  the  predominant  forms  seen  in  the  peripheral  circulation  are  
the  erythrocytes  infected  with  the  ring  stage. Soluble  products  of  
plasmodia  species  known  as  malarial  toxins  cause  systemic  release  
of  proinflammatory  cytokines  such  as  tumour necrosis factor (T.N.F)  
which  acts  on  many  other  systems  like  endothelium.
  
   The   parasite  antigens  may  stimulate  T-cells  to  secrete, or 
induce  production  of  cytokines  from  other  cells. Some T-cells  subset  
secrete  interferons  and  other  cytokines  and  may  facilitate  production  
of  T.N.F  by  monocytes; this  may  have  potentiality  to  be  involved  
in  the  disease  pathogenesis. Both  interferons  and  T.N.F  may  play  
roles  in  dyserythropoeitic  anaemia, and  T.N.F  may  contribute  to  
cerebral  malaria  as  a result  of  up-regulation  of  intracellular  adhesion  
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molecule-1 (ICAM-1) in  cerebral  blood  vessels  endothelium which  
acts  as  a cytoadherence  receptor  for  P.Falciparum, and  probably  it  is  
the  major  vascular  ligand  for  cytoadherence  within  the  brain(14). The  
apparent  adverse  effect  of  pro-inflammatory  cytokines  on  the  host  
are  balanced  by  evidence  of  their  antiparasitic  effect. These  
cytokines  synergize  with  others  defense  mechanisms  to  limit  parasite  
multiplication. On  the  other  hand, interleukin-10 (IL-10)  inhibit  the  
ability  of malarial  antigens  to  induce  or  release T.N.F, and  severe  
malaria  is  associated  with  low  level  of  IL-10 (14).  
Anaemia: 
               Anaemia  is an  inevitable  consequence of  malaria, especially  
in  children(15).  Its  development  is  directly  related  to  density  of  
parasitaemia. The  mechanisms  are  multifactorial  and  complex, 
involving  haemolysis  and  inappropriate  bone  marrow  response (16). 
Cytokines, notably T.N.F, are  known  to  depress  erythropoiesis  and  
contribute to dyserythropoiesis. Immune  mediated  haemolysis  has  been  
suggested as  the  mechanism  of  anaemia  among  children  in  the  
holoendemic  area  of  West  Africa. There  was  evidence  that  red  cells  
were  synsitized  with  C3(17). 
Jaundice: 
 
Hyperbilirubinaemia  is  attributable  to  intravascular  haemolysis  
of  parasitized  erythrocytes, hepatic  dysfunction, and  possibly  an  
element  of  microangiopathic  haemolysis  associated  with disseminated 
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intravascular coagulation (DIC)  and  it  is  more  common  in  adult  than  
in  children (18). 
Liver  dysfunction  may  affect  drugs  clearance  and  contributes  
to  lactic  acidosis. There  is  sequestration  in  hepatic  microvasculature, 
and  in  severe  infection  liver  blood  flow  compromised. Acute  malaria  
adversely  affects  the  function  of  broad  array  of  cytochrome  P450  
microsomal  enzymes  and  also  impair  conjugation  reactions. Liver  
biopsy  usually  reveals  Kupffer  cells  hyperplasia  and  mononuclear  
cells  infiltration(18). 
Cerebral Malaria 
     Any  pathophysiological  explanation  of  the  mechanism  underlying  
cerebral  malaria  must  take  into  account  the  clinical  and  the  
pathological  features  of  this  condition. The  mortality  of  cerebral  
malaria  ranges from  10 to 50% in  treated  patients (19).Unfortunately  
there  is  no  animal  model  which  satisfactory  reproduce  either  the  
clinical  or  the  pathological  features  of  cerebral malaria in human (20). 
This  has  hampered  progress  in  understanding  the  pathophysiological  
mechanisms, and  has  led  to  several  hypothesis  to explain  the  
pathophysiology: 
     A-Mechanical  hypothesis    
This hypothesis attempts to explain the  pathophysiology of                       
severe  falciparum  malaria  by  microcirculatory  obstruction,  with  
resultant  local  hypoxia  and  substrate  depletion. Two  principal  
mechanisms  have  been  proposed  to  account  for  such  
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obstruction, but  in  both  cases  there  is  congestion  of  capillaries  
with  red  cells  containing  mature  trophozoites  and  schizonts.  
      1-Decreased  deformability:-                                                                    
          Normal  erythrocytes  must  undergo  considerable  
deformation  in order  to  transfer  through  the  capillaries, and  
when  erythrocytes  are  unusually  rigid, obstruction  may  occur. 
This  best  illustrated  in  the  crises  of   sickle  cell  disease. It  has  
been  argued  that  erythrocytes  containing  mature  parasites  
might  be  retained  in  the  capillaries  by  similar  mechanism. 
Studies  have  shown  that  P.Falciparum  infected  erythrocytes  have  
reduced  deformability, which  is  directly  proportional  to the  
maturity  of  the  intracellular  parasite (21).                                              
1-   Cytoadherence:-                                                                      
                   Pathological  studies  suggest  intimate  opposition  of       
endothelial  and  infected  erythrocytes  membranes  and  this  has  led  to 
a belief  that  there  is  a  specific  molecular  interaction  which  causes  
infected  erythrocyte  to  adhere  physically  to  endothelium. Uninfected  
erythrocytes  will  also  bind  to  the  surfaces  of  erythrocytes  containing 
mature  forms  of  the  parasite  by  a mechanism  similar  to  that  of  
cytoadherence  to  endothelial  cells  causing  rosetting. This  may  be  
important  in  the  sequence  of  events  leading  to  microvasculature  
obstruction, but  has  not been  demonstrated  in   vivo  in  human (22). 
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B-  The  immunological  hypothesis      
                The  immune  mechanism  appear  to  be  important  in  the  
pathogenesis  of  cerebral malaria in  mice (23). Malaria  infections  
induce  both  cellular  and  humoral  immune   responses, and  there  is  
evidence of complement activation in acute malaria in man (24).Immunity  
is  stage  specific, in  that  immunity  to  either  sporozoites  challenge  or  
to  gametocytes  transmission  does  not  protect  against    asexual  form, 
also  it  is  specific  for  parasite  species, strain, and  antigenic  variant  
within  a strain (25). The  neuropathological  findings  in  cerebral  
malaria  have  been  interpreted  as  resulting  from  hyperergic  reaction  
of     the    central     nervous    system  to  the   antigenic   challenge  of  
P. Falciparum  infection (26). 
Gastrointestinal  dysfunction 
          Minor  ulcerations  of  the  stomach  and  duodenum  is  common  
in  severe  malaria. The  pattern  of  malsabsorption  of  sugar, fat  and  
aminoacid, suggests  splanchnic  hypoperfusion (27,28,29,30). This  results  
from  gut  sequestration  and  visceral  vasoconstriction, and  there  may  
be  increased  gut  permeability  or  reduced  local  defense  against  
bacterial  infection. Antimalarial  drugs  absorption  is  remarkably 
unaffected  in  uncomplicated  malaria (31).    
Spleen 
        There  is  considerable  splenic  enlargement  in  malaria, an increase  
in  capacity  of  the  spleen  to  clear  red  cells  from  the  circulation  
both  by  receptor  mediated (immune) mechanism (32,33) and  by  
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recognition  of  reduced  deformability(34). The  spleen  may  also  
modulate  cytoadherence  and  plays  a role  in  limiting  the  acute  
expansion  of  malaria  infection  by  removing  parasitized  erythrocytes  
and  this  has  led  to  suggestion  that  failure  to  augment  splenic  
clearance  sufficiently  and  rapidly  may  be  a factor  in  development  of  
severe  malaria (35,36). 
 
Metabolic  dysfunction 
             In  severe  malaria, arterial, venous, capillary  and  cerebrospinal  
fluid  concentration  of  lactate  rises  in  direct  proportion  to  severity  of  
the  disease. Lactic  acidosis  is  an  important  cause  of  death  and  it  
results  from  several  discrete  processes:- the  tissue  anaerobic  
glycolysis  consequent  upon  microvasculature  obustruction, failure  of  
hepatic  and  renal  lactate  clearance  and  production  of  lactate  by  the  
parasite (37,38,39). Mature  malaria  parasite  consume  up  to  70  times 
as  much  glucose  as  an  uninfected  cell, and  over  90% of  it converted  
to  lactic  acid.  Plasmodia  do  not  have  complete  set  of  enzymes  
necessary  for  citric  acid  cycles. Lactate  level  also  rise   after  
generalized convulsions. Hyperlactataemia is accompanied by  
hyperalaninaemia, reflecting  the  impairment  of  gluconeogenesis (40) ; 
lactate  and  alanine  are  the  major  precursors  for  gluconeogenesis. 
Triglyceride  and  free  fatty  acids  levels  are  also  elevated  in  acute  
malaria(41).     
           In  severe  malaria  there  is  dysfunction  of  all  organ  systems, 
particularly  those  with  obligatory  high  metabolic  rates. Pitutary-
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thyroid  axis  abnormalities  result  in  sick  thyroid  syndrome  and  also  
parathyroid  dysfunction (42), by  contrast  the  pitutary-adrenal  axis  
appears  normal  in  acute  malaria (43). 
Hypoglycaemia  
           Hypoglycaemia  is  increasingly  recognized  as  a complication  of 
falciparum  malaria  and  it's  treatment. Usually  it  is  not  suspected  
clinically  because  of  the  patient  poor  clinical  state. Hypoglycaemia  
complicates  malaria  in  three  clinical  settings  which  may  overlap:-in 
patients  given  quinine, in  pregnant  women  and  in  patients  with  
severe  disease. Quinine  induced  hyperinsulinaemia  was  the  
commenest  cause  of  hypoglycaemia  in  Thailand; it  was  seen  in  
adult, pregnant  women  and  in  children (40), and  has  also  been  
reported  in  adult  and  in  children in  Zair (44) and  in  adult  in  
India(45). Pregnant  women  may  develop  hypoglycaemia  with  or  
without  quinine  treatment (46). Hypoglycaemia  has  been  found  in  
adult  with  severe  manifestations  such  as  cerebral  malaria, severe  
anaemia, jaundice, high  parasitaemia  and  lactic  acidosis  at  a time  
when  their  plasma  insulin  level  was  relatively  low  before  quinine  
therapy (40). 
          Hypoglycaemia  is  associated with  hyperlactaemia  and  share  the  
same  pathophysiological  etiology. The  factors  participate  for  
hypoglycaemia  include:- an  increase  in  peripheral  requirement  for  
glucose  consequent  upon  anaerobic  glycolysis  and  increased  
metabolic  demand  of  febrile  illness, the  obligatory  demands  of  the  
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parasites  which  use  glucose  as  their  major  fuel  and  failure  of  
hepatic  gluconeogenesis (37,40). 
Renal  failure           
 P.Falciparum  malaria  was  the  second  cause  of  renal  failure in  
Ethiopia (47). Many  patients  are  dehydrated  and  the kidney  function 
usually return to  normal  after  dehydration. This  hypoperfusion  may  
result  in  cortical  vasoconstriction, ischaemia and  later  tubular  necrosis 
(48). Renal  microvascular obstruction  may  occur  due  to  sequestration  
in  the  kidney  or  may  be  due  to  immunological  factors (49). 
Black  water  fever 
         This  syndrome  caused by  severe  haemolysis  with  resultant  
haemoglubinuria, it  is  rarely  seen  now, and  may  occur  in  patients  
with  overwhelming  infection  or  with  red  cell  abnormalities  like    
G6PD  deficiency  who  use  quinine  or  primaquine  for  malarial  
treatment. This  syndrome  associated  with  high  mortality( 20-
30%)documented  in  European  and  Asian  working  in  Africa  in  the  
first  half  of  twentieth  century (50). Half  of  these  deaths  were  caused  
by renal  failure  in  patients  partially  treated  with  quinine. 
Pulmonary  edema   
          This  is  a grave  and  usually  fatal  manifestation  of  severe  
falciparum  malaria . A proportion  of  cases  show  evidence  of  fluid  
overload, with  raised  central  venous  or  pulmonary arterial wedge  
pressures (51), others  develop  pulmonary  edema  with  normal  or  
negative  fluid  balance  and  in  the  face  of  normal  or  reduced  
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pulmonary  wedge  pressures (52). Unlike  the  capillary  permeability  in  
other  vascular  beds, the  capillary  permeability  in  pulmonary  beds  
showed  a sudden  increase  and  this  may  be  the  explanation  of  
pulmonary  edema (53). 
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Clinical Features 
  Plasmodium  Vivax  and  Plasmodium  Ovale  Malaria 
        In  many  cases  the  illness  starts  with  a period  of  several  days  of  
continuous  fever  before  the  classical  periodic  fever  with  rigors  
occur. The  patient  feels  cold  and  the  temperature  rises  to  about  
40co, after  short  time  the  hot  or  flushing  phase  begins, it  lasts  
several  hours  and  gives  way  to  a profuse  perspiration  and  gradual  
fall  in  temperature. The  cycle  is  repeated  48 hours  later. Gradually  
the  spleen  and  liver  enlarge  and  may  become  tender, anemia  
develops  slowly, H.Simplex  is  common. Relapses  are  common  in  the  
first  two  years.     
Plasmodium  Malariae  Infection 
         This  usually  associated  with  mild  symptoms  and  bouts  of  
fever  every  third  day. Parasitaemia  may  persist  for  several  years  
with  occasional  recrudescences.  It  is  a recognized  cause   of  nephritic  
syndrome. 
Plasmodium  Falciparum  Infection 
          This  is  more  dangerous  than  the  other  forms  of  malaria. The  
onset, especially  of  primary  attack, is  often  insidious  with  malaise, 
headache, vomiting, cough  and  mild  diarrhoea. The  fever  has  no  
particular  pattern  and  does  not  usually  rise  quite  so  high  as  in  
other  forms  of  malaria. Hot, cold and  sweating  stages  are  seldom  
seen. The  liver  and  spleen  enlarge  and  became  tender. Anaemia  
develop  rapidly. Jaundice  is  common  due  to  haemolysis  and  
hepatitis (10). 
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Parasitological Diagnosis 
          Parasitological  examination  of  the  blood  should  be  available  
in  the primary  health  care  units  and  should  incorporated  into  patient  
management  as  soon  as possible. The  presence  of  malaria  parasite  in  
the  blood  may  be  detected  by  routine  thick  blood  film  examination  
when  densities  are  in  the  order  of  5-10 parasite /ml.of  blood. Thick  
blood  films  are  more  useful  than  thin  films in  the  detection of low  
parasitaemia. Malaria  parasites  may, occasionally, be  discovered  in  the  
examination  of  poorly  prepared  slide  or  in  thin blood films  prepared 
for  differential  blood  count. Thick  blood  films  yield  a much  higher  
concentration  of  parasite  than  thin  films, it  is  useful  when  the  
parasites  are  few  or  thin  films  are  negative. The thick  film  is  not  a 
thick  drop, but  the  smear  spreads  at  thickness  of  0,5 mm  or  less, so  
that  it  is  sufficiently  transparent  for  microscopic  examination  when  
haemoglobin  is  removed. 
             Thick  blood  films  are  not  fixed  with  alcohol, but  the  slide  
with  the  dried  thick  film  is  placed  in  50 ml  diluted  Geimsa  stain. 
After  45 minutes  of  staining,  the  smear  is  carefully  rinsed  with  tap  
or  buffered  water  and  then  allowed  to  dry; 5 minutes  search  of a 
thick  film  should  reveal  parasites  if  present. The stained  thin  dry  
film  permits  the  study  of  the  morphology  of  the  parasite  more  
better than  thick  film. Recent  studies  on  the  parasite  genome  
together  with  the  production  of  pure  malarial  antigens  and  specific  
monoclonal  antibodies, have  resulted  in  development  of  immuno - 
chromatography  test (ICT). This  test  is  especially  useful  when  the  
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patient  has  repeated  negative  films, or the  patient  received  
antimalarial  treatment  for  several  days  and  the  blood  film  was  
negative. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 22
                            Chemotherapy of Malaria 
Chloroquine 
 
         
   It  is  4-aminoquinolone  compound, rapidly  absorbed  after  
oral  administration. In  adult  with  malaria, oral  bioavailability  related  
to  parenteral treatment  is 70%. Intramuscular and subcutaneous 
administrations  of  chloroquine  give  almost identical  plasma  or  whole  
blood  concentration  profile. Peak  plasma  concentration  reached  in  
about  30 minutes  after  parenteral  administration, this  will  result  in  
high  and  potentially  toxic  blood  concentration  if  doses  of  5 mg  
base/kg  or  larger  are  given. Chloroquine  has  enormous  volume  of  
distribution, which  results  from  considerable  binding  in  organs  such  
as  liver, connective  tissues  and  melanin  containing  tissues  such  as  
skin  and  retina. Chloroquine  is  55% protein  bound  in  plasma, 
concentration  in  cerebrospinal  fluid (CSF) is  very  low  with  mean  
value  of  2.7%  of  corresponding whole  blood  concentration (54). The  
drug  is  51% cleared  unchanged  by  the  kidney, is  biotransformed  by  
the  liver,  mainly  to desethyl  and  bisesethyl chloroquine.The principal  
metabolite  desethyl chloroquine  is  less  potent  than  the  parent  
compound  and  it  is  also  eliminated  more  slowly. Although  this  
metabolite  contribute  toward prophylactic  efficiency, it’s  concentration  
is  not   relevant  to  the  treatment  of  severe  malaria. The  terminal  half  
life  of  chloroquine  is  approximately I-2 months, but  for  curative  
treatment, the  biological  half  life  is  about  6- 10 days. 
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Acute Toxicity  
             Oral  chloroquine  is  usually  well  tolerated, nausea, headache, 
uneasiness  and  dysphoria  are relatively  common; patients  may  vomit  
and  may  complain  of  blurred  vision. Postural  hypotension  associated  
with  malaria  may  be  exacerbated  by  chloroquine  and  pruritis  may  
be  severe. Chloroquine  over  dose  is  manifested  by hypotension,  
dysrhythmia,  convulsion  and  coma.  
Chronic  Toxicity 
            Administration  of  chloroquine  for  long  time - years – as  a 
prophylactic  or  in  case  of  rheumatoid  arthritis  was  associated  with  
significant  risk  of  retinopathy. Skeletal  and  cardiac  myopathy may  
also  occur  in  patient  receiving  high  dose  of  chloroquine. 
Chloroquine  can  aggravate  psoriasis (55). 
Quinine 
 
        
 Quinine  is  the  treatment  of  choice  for  severe  malaria. It  is  a 
cinchona  alkaloid, quinine  sulphate  is  well  absorbed  when  given  
orally. Peak  plasma  concentration  is  reached  in  1-3 hours. The  
parenteral  form  is  quinine dihydrochloride  which  should  not  be  
given  subcutanously  because  it  can  result  in  skin necrosis. When  
given  intravenously, it  should  be  diluted  with  normal  saline  or  
dextrose  and  given  over 2-3 hours. Intramuscular  quinine  is  certainly  
painful  if concentrated  acidic  solution  are  administered. Quinine  is  a 
base  and  the  principal  plasma  protein  to  which  it  binds  is  the acute   
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phase  protein, which  increases  in  malaria, and  therefore  during  the  
illness  quinine  is  less  toxic. 
        Quinine  is  predominantly –80%- eliminated  by  hepatic  
biotransformation, first  to  3 and 2- hydroxyquinine, and  then  to  a 
series  of  more  water  soluble  metabolites. 20% of  the  quinine  is  
eliminated  by  the  kidneys. The  mean  terminal  elimination  half  life  
in  healthy  adult is  11 hours  compared  with  16 hours  in  
uncomplicated  malaria patient  (51,52,53,54,55,56).
 
Toxicity 
         Minor adverse reactions are common with quinine therapy. A     
chracteristic   symptoms  complex  known  as  cinchonism  with a plasma  
concentration  over 5mg/litre. This  consists  of  tinnitus, high  tone  
deafness, nausea, uneasiness, dysphoria, blurring  of  vission  and 
vomiting. Severe  toxicity  may  lead  to  hypotension, myocardial  
conduction  disturbances, deafness, hypoglycaemia  and  coma. Quinine  
is  a potent  stimulant  to  pancreatic  insulin  secretion. Postural  
hypotension  is  common  in  acute  malaria  and  this  may  be  
exacerbated  by  quinine  therapy. Thrombocytopenia, Comb's  positive  
haemolytic  anaemia  and  other  haemolytic  reactions  are  rare (55)..  
Mefloquine 
           It  is  a quinolone methanol  compound  which  structurally  
resemble  quinine. It  is  effective  against  all  malaria  species  including  
multi  drug  resistant  P.Falciparum, although  resistant  parasites  
population  occur  naturally. Mefloquine  is  well  absorbed  and  highly  
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bound  to  plasma  protein (98%), and  exhibit a multiexponential  decline  
in  blood  concentration  with  a terminal elimination  half  life  of  three  
weeks. Clearance  is  by  hepatic  biotransformation. No  parenteral  
preparation  is  available, oral  suspension  is  better  absorbed  than  
tablet(57). 
Toxicity 
       Dizziness, nausea,  vomiting  and  GIT upset  are  common. 
Headache,  bradycardia, skin  reactions  and  neuropsychiatric  
disturbances  are  rare  manifestations (57). 
Sulphadoxine-Pyrimethamine (Fansidar) 
       This  is  the  most  used  of  a family of  drugs  combination  which  
antagonize  parasite  folic  acid  synthesis. They  act  by  inhibition  of 
dihydropteroate  synthesis (sulphonamide) and  dihydrofolate  reductase  
synthesis (Pyrimethamine). The  combination  is  well  absorbed, plasma  
protein  binding  of  both  component  in  healthy  subject  is  high 
(pyrimethamine 93%, sulphadoxine 88%). Pyrimethamine  is  cleared  
predominantly  by  hepatic  biotransformation  and  the terminal  
elimination  half  life  is  approximately  90 hours.  Only  5%  of  
sulphadoxine  is  acetylated  and  secreted  in  the  urine  in  this  form, 
the  terminal  elimination  half  life  is  approximately  180 hours. 
Toxicity  
           Oral  sulphadoxine- pyrimethamine  may  provoke  folate  
deficiency  in  vulnerable  subjects (pregnant  and  malnourished  
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patients). Sulphonamide  should  not  be  given  in  late  pregnancy  or  to  
the  newborn  because  of  the  rare  risk  of  provoking  kernicterus. 
Severe  allergic  cutaneous  reactions  are  the  most   common  serious  
adverse  reactions (erythema  multiforme and  Steven-Jonson syndrome ). 
Agranulocytosis  and  other  blood  dyscrasias, hepatitis,  pulmonary  
eosinophilia  and  neuropathy  have  been  reported (58). 
Qinghasosu (Artemisinin).  
       It  is  a sesquiterpene  lactone  peroxide  extracted  from  leaves of  
the  plant  artemisia  annua.  Two  derivatives  are  widely  used: the lipid  
soluble  methyl  ether  artemether,  and  the  water  s o l u b l e   
hemisuccinate  derivative  artesunate. These  drugs  are  the  most  rapidly  
acting  of  the  known  antimalarials; they  also  have  abroad  time  
window  of  antimalarial  effect  from  ring  forms  to  mature  
trophozoites. Artemisinin  is  available  as  capsules  of  powder  or  as  
suppositories. Artemether  is  formulated  in  Sesame   oil  for  
intramuscular  injection. Artesunate  is  formulated  either  as  tablets  or  
as  dry  powder  of  artesunic  acid  for  injection, supplied  with  ampoule  
of  5% sodium  bicarbonate. The  powder  is  dissolved  in  sodium  
bicarbonate  to  form sodium  artesunate, and  then  diluted  in  5% 
dextrose  or  normal  saline  for  intravenous  or  intramuscular  injection.  
Artether  is  very  similar  compound  to  artemether. It  is  the  oil  
soluble  ethyl  ether  and  will  be  given  by intra  muscular  injection. 
Toxicity  of  the  artemisinin  related  compounds  such  as  depression  of  
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reticulocyte  count, neurotoxicity  and  gut  toxicity  appear  rarely  and  
at  higher  doses (57). 
Halofantrine 
         This  is  a phenanthrene-methanol  compound. It  is  dispensed  in  
tablets  and  no  parenteral  preparation. The  drug  has  low  oral  
bioavailability; it  is  recommended  that  halofantrine  doses  are  better  
divided  in  three  doses  at  six  hour  intervals. Oral  bioavailability  can  
be  increased  two  to three  folds  if  the  drug  is  taken  with  fatty  
meals. Halofantrine  is  almost  entirely  eliminated  by  hepatic  
biotransformation. The  terminal  elimination  half  life  is 3-4 days. 
Toxicity 
          Halofantrine  is  generally  well  tolerated. Abdominal  pain  and  
diarrhoea  occur rarely. Intravascular  haemolysis, cardiac toxicity   and  
hypersensitivity  reactions  have  been  reported (58). 
Primaquine 
        It  is  an  8- aminoquinolone  compound. Absorption  is  essentially  
complete,  peak  plasma  concentrations  are  reached  in  6 hours. 
Effective  clearance  of  tissue  schizonts  does  not  begin  until  
primaquine  udergone biodegradation  by  demethylation  and  oxidation  
to  quinolone- quinone  derivatives, the  active  antimalarial  and  
haemolytic agents. Only 1%  is  excreted  unchanged  in  the  urine. It  
acts  on  the  exorythrocytic  stages  and  has  practically  no  effect  on  
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the  erythrocytic  stages. It  postulated  that  both  tissue  schizonts  and  
the  G6PD deficient  erythrocytes  have a deficiency  of  an  enzyme  or  
cofactor  in  the  pentose  phosphate  pathway,  making  them  susceptible  
to  oxidative  dammage. Primaquine  also  has  gametocidal  effect, 
making  it  the  best  available  drug  to  interrupt  the  transmission  of  
malaria. 
Toxicity 
         Toxic  reactions  often  seen  when  large  doses (60-240 mg)  are  
given, including headache, pruritis, leucopenia  and  
methaemoglbinaemia. Severe  haemolysis  occurs  in   susceptible  
individuals (58). 
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Objective 
a. To evaluate the clinical and parasitological responses 
to different quinine doses. 
b. To evaluate the toxicity and adverse drug reactions 
among the patients. 
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Methodology 
Study  Area 
         The  study  was  carried  out  in  New Halfa, an  agricultural  area  
in  Eastern  Sudan, 500Km  from  khartoum. It  is  450M  above sea  
level, located  between  15- 19 lat .North  and  35- 36 long. East. The  
average  annual  rain  fall  is  238mm  and  the  average  relative  
humidity  is  35%. There  are  two  major  agricultural  schemes  with  
permanent  irrigation  system. The  area  is  made  up  of an  isovillages 
constituting  400,000 individuals.  The  health  services  obtained  by  one 
teaching  hospital, one  single  doctor  hospital  and  50  primary  health  
centres. It  is  mesoendemic  for  malaria  with  a peak  of  transmission  
following  the  rainy  season. The  predominant  malaria  parasite  is  
P.Falciparum. 
Patients 
        Patients  presented  to  the  primary  health  centre (Elhara Eloula), 
during  the  study  period, ( Dec.2002 to Feb.2003) with  symptoms  
suggestive  of  malaria  after completing  full  course  of  chloroquine  
were  included  after  verbal  consent  from  the  patients  or  the  parents  
in  case  of  children.  
Exclusion  Criteria 
1-Pregnant  women. 
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2-Chronic  debilitating  illness. 
3-Patients  with  severe  malaria. The  diagnosis  of  severe  malaria  
according  to  W.H.O  criteria (59)was  made  if  the  patient  presents  
with  one  or  more  of  the  following  features: 
1 –Cerebral  malaria (unrousable coma), failure  to  localize  or  to  make  
an  appropriate  verbal  response  to  noxious  stimulus. 
2-Shock (circulatory  collapse)  systolic  blood  pressure  of  80mm/Hg  
or  less  with  cold  extremities.   
3-Jaundice  detected  clinically  or  when  the  total  bilirubin  is  3mg/dl 
or  more. 
4-Impairment  of  consciousness  less  marked  than  unrousable  comma. 
5-Prostration  or  weakness  so  that  the  patient  can  not  sit  or  walk  in  
the  absence  of  obvious  neurological  explanation. 
6-Severe  anaemia, haemoglobin  of  less  than  5gm/dl. 
7-Pulmonary  oedema. 
8-Macroscopic  haemoglobinuria. 
9-Renal  failure  with  serum  creatinine  more  than  3mg/dl. 
10-Repeated  generalized  convulsions – more  than  two  observed  
within  24hours  despite  cooling. 
11-Hypoglycaemia  defined  as  blood  glucose  40mg/dl  or  less. 
12-Spontaneous  bleeding. ( from  gums, nose  and  gastrointestinal  
tract.) 
13-Hyperparasitaemia  of  more  than  250000 rings/ul. 
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A questionnaire containing  sociodemographic  information,  clinical  
examination  and  investigations  was  filled  for  every  patient. 
Investigations: 
        Using  finger  prick  blood, thick  and  thin (if  the  species  were  
doubted)blood  smears  were  prepared  from  each  patient, stained  with  
Geimsa(PH7.0,diluted  in PBS) and  the  parasite  counted  against  200  
white  blood  cells (WBCs) assuming  that  the  number  of  WBCs  is  
6000/ul of  blood. The  blood  films  were  prepared  and  examined  by  
highly  expert  technician  and  crossed-checked  by  another  technician  
blinded  about  the  results  and  verified  by  a supervisor  if   there  was  
any  controversy.  
            All  patients  were  staying  in  the  same  area  during  the  follow  
up  period. Therefore, the  possibility  of  reinfection  or  recrudescence  
was  present. Three  spots  of  blood  were  taken  on  filter  paper  
initially  and  later  if  parasites  reappeared  microscopically  during  the  
follow  up  period. Primers  from  3 polymorphic  P.Falciparum  
antigens; merozoite  surface  protein-1 and 2 (MSP-1 and MSP-2)  and  
glutamate-rich  protein  (GLURP) were  used  in  polymerase  chain 
reaction (PCR)  to differentiate  between  true  recrudescence  and re-
infection. 
Treatment  And  Follow  Up 
          The  patients  were  randomized  in  three  groups  by  using  three  
boxes, each  box  contains  five  envelopes  to  prevent  the  bias. Group 1 
treated  with  quinine  sulphate  tablets (Elie  pharmaceuticals, Khartoum, 
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Sudan) 10 mg/kg  three  times  daily, group  2  with 10mg/kg  twice  daily  
whereas  group  3 treated  with  15 mg/kg  once daily. Duration  of  
treatment  is  one  week  for  each  group. In  case  of  children  who  can  
not  swollow  the  drug, the  tablet  was  disolved  in  water  and  then  
given  orally. The  medicine  was  given  under  close  supervision  of  the  
team, the  dose  repeated   for  those  who  vomited  the  drug  within  one  
hour, if  the  patient  vomited  again , the  dose  was  given  by  
intravenous  quinine  infusion  in  5% dextrose  slowly  over  two  hours, 
then  it  was  continued  as  tablet  to  complete  one  week  treatment.  
          All  patients  were  followed  up –according  to WHO  protocol – 
clinically  daily  for  seven  days, then  weekly  for  three  weeks, blood  
films  were  obtained  and  examined  microscopically  to  detect  parasite  
clearance  time (from  start  of  treatment  till  first  negative  film)  and  
reappearance  of  parasitaemia. 
           The  patients  were  sensitive  to  the  treatment  if  after  
administration  of  the  drug  the  blood  film  became  negative  before  
day  seven  and  remained  negative  for  the  following  three   weeks. 
They    were  considered  as  early R-1  resistance  when  the  parasite  
disappeared  for  at  least  two   consecutive  days  and  reappeared  on  
day  seven  or  day  fourteen, while  they  were  considered  late  R-1 
resistance  when  recrudescence  occurred  on  day  twenty  one  or  
twenty  eight. Patients  were  considered  to  have  R-2  resistance  if  
parasitaemia  never  cleared  within  the  first  seven  days, but  was  
reduced  to  25%  or  less of  parasitaemia  level  during  the  first  48  
hours  of  the  treatment. R-3 resistance  grade  patients  reduce  
 34
parasitaemia  level  by  less  than  75%  during  the  first  48 hours  of  the  
treatment  or  it  continue  to  rise. 
During  the  follow  up  period, all  patients  were  asked  about  
recurrence  of  symptoms, adverse  drug  reactions  and  informed  not  to  
take  any  other  medication  without  consulting  the  team. Patients  who  
failed  to  take  the  drug  for  two  days  were  withdrawn  from  the  
study, resistant  cases  were  treated  by  an  alternative  drug. The  
medicine  was  supplied  to  all  patients  free  of  charge. 
Statistical  Analysis        
             Data  was  entered  into  a computer  database. SPSS  software  
was  used  for  statistical  analysis. Differences  in  percentage  of  
resistance and  side  effects  were  compared  between  the  first,  second  
and  the  third  group  using  X2 test. The  differences  in  the  mean  age, 
weight, initial  parasitaemia, the  mean  temperature  and  mean  parasite  
clearance  time (in days)  were   calculated  by  ANOVA  one-way  
analysis. P < 0 .05  was  regarded  significant. 
Ethical  clearance  
       The  study  received  ethical  clearance  from  the  faculty  research  
board  at  the  Faculty  of  Medicine, University  of  Khartoum. 
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Results 
 
           During  the follow up  period,  720  patients  presented  to  the  
primary  health   centre  with  symptoms  suggestive  of  malaria,  400 
(56%) have  positive  blood  films  for  malaria,12  patients  have severe  
malaria, 98 patients  presented  with  falciparum  malaria  after  
chloroquine  failure. Ninety three  fulfilled  our  selection  criteria  and  
completed  the  28 days  follow  up, 32, 31 and 30  were  assigned  to  
group 1, 2 and 3  respectively. Five  patients; 2  in  group 1, 1 in  group 2, 
and 2 in  group 3  were  lost  during  the  follow up  period  because  they  
changed  their  addresses. 
          The  mean  age  is  16.34 years  in  group 1, 16.69 years  in  group 
2  and 15,93 years  in  group 3(P=>0.05). 
          The  mean  weight  is  29.32kg in  group 1, 34.54kg in  group 2  
and  33.66kg  in  group 3(P=>0.05). 
            The  mean  temperature  is  38.28C in  group 1, 37.98C  in  group 
2  and  38.38C  in  group 3 (P=>0.05). 
          The  mean  parasite  clearance  time(PCT) is 2.8 days  in  group 1, 
3.1 days  in  group 2  and  2.8 days  in  group 3 (P=>0.05). 
           Due  to  intractable  vomiting  the  initial  quinine  dose  was  
given  parenterally  in  1/32(3.1%), 4/31(12.9%)  and 4/30 (13.3%) 
patients  in  group  1, 2 and  3, respectively (the  difference  was  not  
statistically  significant). 
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           The  number  of  children  is 7(21.9%) in  group 1, 5 (16.1%) in  
group 2, and  6 (20%) in  group 3. 
            The  number  of  males  is  23 (71.9%) in  group 1, 14 (45.2%) in 
group 2  and 13(43.3%) in  group 3,whereas   the  number  of  females  is  
9 (28.1%) in  group1, 17 (54.8%) in  group 2 and 17 (56.7%)in  group 3 
(Table 1).                                                                                                                          
            The  number  of  patients  presented  with  fever  is 31 (96.9%) in  
group 1, 30 (96.8%) in  group 2  and 29 (96.7%) in  group  3 (Table 2). 
             Table 3 showed that headache  was  recorded  in 76.3% of the 
patients.     
            Vomiting  was  recorded  in  19(59.4%) in  group 1, in 15(48.4%) 
in  group 2 and  in 14(46.7%) patients in  group 3(Table 4). 
            Sweating  was  observed   in 13(40.6%) in  group 1, in 12(38.7%) 
in  group2  and  in 9(30%) patients  in  group 3(Table 5). 
            Chills was  present  in 23(71.9%) in  group 1, in 23(74.2%) in  
group 2  and  in  17(56.7%) patients  in  group 3. 
Table 6 showed that  spleen  was palpable  in 12.9% of the 
patients.                                                                                                                                  
.         The  number of  patients  who  have  fever  on  day  3  is  7 (21.9%) 
in  group 1, 9 (29%) in  group 2 and 11 (36.7%) in  group 3 (Table 7).  
             There was no significant   difference  in  the  mean temperature 
on day 3  between the  three  groups,  but    the  mean  (SD) fever 
clearance times in days was significantly longer in group 2(BD) in 
comparison with the other two groups (TDS and Once),3 3.5(2.1) vs. 
2.3(1.6)and3.5(2.1)vs.2.2(1.3),P<0.05.                                                                 
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.         Table 8 showed  that tinnitus  was  recorded  in 46.2% of the 
patients after receiving quinine treatment. 
The  mean(SD) parasite  clearance  time  was 2.8(0.49) in  group 1, 
3.1(0.45) in  group 2  and 2,8(0.92) in  group 3 (Table 9). The  difference  
was  not  statistically  significant ( P=>0.05). 
The  mean  parasite  count  was  8971.87/mm  in  group 1, 
9100/mm  in  group 2  and  8383.3/mm  in  group  3. 
            Parasitaemia  was detected  during  the  follow  up  on  day 28  or 
before  in 2(6.3%) in  group 1, in 5(16.1%) in  group 2 and 5(16.7%) 
patients  in  group 3; the  difference  was  not  statistically  significant 
(P>0.05). The  parasitaemia  detected  was  due  to  true  recrudescence  
in  the  first  and  second  group , except  for  one  patient  in  the  second  
group  where  it  has  been  shown  to  be  due  to  re-infection. This re-
infection  was  detected  on  day 21. Parasitaemia  was  detected  in  5 
patients from  group 3  during  the  follow-up; two  of  them  were  true  
recrudescence  detected  on  day 14, one  case  detected  on  day 21(re-
infection), whereas two  patients  detected  on day  28; one  was  due  to 
re-infection  and  the  other case  was due  to  true  recrudescence.   
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Table (1) :- 
Sex distribution among the three treatment groups 
 
Groups Sex 
Group I Group II Group III 
Total 
Male Count 23 14 13 50 
 %Within the group 71.9% 45.2% 43.3% 53.8% 
 % of total  24.7% 15.1% 14.0% 53.8% 
female Count 9 17 17 43 
 %Within the group 28.1% 54.8% 56.7% 46.2% 
 % of total 9.7% 18.3% 18.3% 46.2% 
Total Count 32 31 30 93 
 %Within the group 100.0% 100.0% 100.0% 100.0% 
 % of total 34.4% 33.3% 32.3% 100.0% 
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Table (2 ) :- 
Fever among the three treatment  groups 
 
Groups 
Fever Group I Group II Group 
III 
Total 
Count 1 1 1 3 
%Within the 
group 
3.1% 3.2% 3.3% 3.2% 
Afebrile 
% of total 1.1% 1.1% 1.1% 3.2% 
Count 31 30 29 90 
%Within the 
group 
96.9% 96.8% 96.7% 96.8% 
Febrile 
% of total 33.3% 32.3% 31.2% 96% 
Count 32 31 30 93 
%Within the 
group 
100.0% 100.0% 100.0% 100.0% 
Total 
% of total 34.4% 33.3% 32.3% 100.0% 
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Table (3 ) :- 
Headache  among the three treatment groups 
 
Groups Headache 
Group I Group II Group III 
Total 
Count 6 11 5 22 
%Within the group 18.8% 35.5% 16.7% 23.7% 
No headache 
% of total 6.5% 11.8% 5.4% 23.7% 
Count 26 20 25 71 
%Within the group 81.3% 64.5% 83.3% 76.3% 
Headache 
% of total 28.0% 21.5% 26.9% 76.3% 
Count 32 31 30 93 
%Within the group 100.0% 100.0% 100.0% 100.0%
Total 
% of total 34.4% 33.3% 32.3% 100.0%
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Table (4 ) :- 
Vomiting  among the three treatment groups 
 
Groups 
  Vomiting 
Group I Group II Group III 
Total 
Count 13 16 16 45 
%Within the group 40.6% 51.6% 53.3% 48.4% 
No vomiting 
 
% of total 14.0% 17.2% 17.2% 48.4% 
Count 19 15 14 48 
%Within the group 59.4% 48.4% 46.7% 51.6% 
Vomiting 
% of total 20.4% 16.1% 15.1% 51.6% 
Count 32 31 30 93 
%Within the group 100.0% 100.0% 100.0% 100.0%
Total 
% of total 34.4% 33.3% 32.3% 100.0%
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Table (5 ) :- 
Sweating among the three treatment groups 
 
Groups 
   Sweating 
Group I Group II Group 
III 
Total 
Count 19 19 21 59 
%Within the 
group 
59.4% 61.3% 70.0% 63.4% 
No 
sweating 
% of total 20.4% 20.4% 22.6% 63.4% 
Count 13 12 9 34 
%Within the 
group 
40.6% 38.7% 30.0% 36.6% 
Sweating 
% of total 14.0% 12.9% 9.7% 36.6% 
Count 32 31 30 93 
%Within the 
group 
100.0% 100.0% 100.0% 100.0%
Total 
% of total 34.4% 33.3% 32.3% 100.0%
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Table (6) :- 
Splenomegaly among the three treatment  groups  
 
Groups 
   Splenomegaly 
Group I Group II Group III 
Total 
Count 29 27 25 81 
%Within the group 90.6% 87.1% 83.3% 87.1% 
No 
splenomegaly 
% of total 31.2% 29.0% 26.9% 87.1% 
Count 3 4 5 12 
%Within the group 9.4% 12.9% 16.7% 12.9% 
Splenomegaly 
% of total 3.2% 4.3% 5.4% 12.9% 
Count 32 31 30 93 
%Within the group 100.0% 100.0% 100.0% 100.0% 
Total 
% of total 34.4% 33.3% 32.3% 100.0% 
 
 44
Table (7) :- 
Fever on day 3 among the three treatment groups 
 
Groups 
Fever on day 3 
Group I Group II Group 
III 
Total 
Count 25 22 19 66 
%Within the 
group 
78.1% 71.0% 63.3% 70.7% 
Afebrile 
% of total 27.2% 22.8% 20.7% 70.7% 
Count 7 9 11 27 
%Within the 
group 
21.9% 29.0% 36.7% 29.3% 
Febrile 
% of total 7.6% 9.8% 12.0% 29.3% 
Count 32 31 30 93 
%Within the 
group 
100.0% 100.0% 100.0% 100.0%
Total 
% of total 34.4% 33.3% 32.3% 100.0%
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Table (8):- 
Tinnitus  among the three treatment groups  
 
Groups 
Tinnitus 
Group I Group II Group 
III 
Total 
Count 15 20 15 50 
%Within the 
group 
46.9% 64.5% 50.0% 53.8% 
No 
tinnitus 
% of total 16.1% 21.5% 16.1% 53.8% 
Count 17 11 15 43 
%Within the 
group 
53.1% 35.5% 50.0% 46.2% 
Tinnitus 
% of total 18.3% 11.8% 16.1% 46.2% 
Count 32 31 30 93 
%Within the 
group 
100.0% 100.0% 100.0% 100.0%Total 
% of total 34.4% 33.3% 32.3% 100.0%
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Table (9) :- 
Resistance  among the three treatment groups 
 
Groups 
Resistance 
Group I Group II Group 
III 
Total 
Responsive Count 30 26 25 81 
 %Within the 
group 
93.8% 83.9% 83.3 87.1% 
 % of total 32.3% 28.0% 26.9% 87.1% 
Resistant Count 2 5 5 12 
 %Within the 
group 
6.3% 16.1% 16.7% 12.9% 
 % of total 2.2% 5.4% 5.4% 12.9% 
Total Count 32 31 30 93 
 %Within the 
group 
100.0% 100.0% 100.0% 100.0%
 % of total 34.4% 33.3% 32.3% 100.0%
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Discussion 
        Our  study  showed  that  quinine  dose  could  be  reduced  
effectively, even  to  single  dose  per  day (15mg/kg), as  there  was  no  
significant  difference   in  the  rate  of  reappearing  of  parasitaemia  
between   the  three  groups. P. Deloran  and  colleagues –Madagascar-  
studied  the  effect  of  short  term  oral  quinine  in  treatment  falciparum  
malaria  in two different groups treated for different periods  and  
followed  up  for  two  weeks. The  first   group  treated for two days  
whereas  the  second  group  treated  for  three  days. Parasitaemia 
reduced by 97% on day 14 in group two and was more than six times 
lower than that in group one ( 60).In  that  study  the  follow  up   period  
was  relatively  short, and  some  cases  of  true  recrudescence  might  not  
be  detected  during  this  period. In  our  study  most  cases  of  re-
infections  and  recrudescence  occurred  after  day  14, also  in  this  
study  the  duration  of  the  treatment  was  shorter  than  in  our  study,  
and  the  duration  of  the  treatment  and  the  total  daily  dose  were  
different  in  the  two  groups ; these    factors  make  the comparison  
difficult.    
         Kofoed et al. studied  the  effect  of  different  doses  of  quinine  in  
Guinea-Bissau  in  children treated for seven days. This  study  indicated  
that  treatment  of  non  severe  falciparum  malaria  with  single  daily  
dose  of  15mg  quinine salt/kg  is  sufficient. Apparently  pre-existing  
immunity  has  contributed  to  the  clearance  of  parasite; antimalarial-
drugs    are  more  effective  in  semi-immune  subjects  than  in  non  
immune, as  the  patient's  immune  system  adds  to  the  effect  of  the  
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drug(61). No significant  differences  were  found  between  the  quinine  
concentration  in the  blood  in   children who  had    and   children  who  
did  not  have   recurrent  parasitaemia  in  any  of  the  treatment  groups, 
indicating  that  the  length  of  treatment  is  more  important  than   the  
doses ,however, the  drug  concentrations  were  significantly  higher  in  
group 1 than  in  group 2  and  group 3, but  also  in  group 2  as  
compared  to  group 3(62). It  has  generally  been  assumed  that  
antimalarial  blood  concentrations  should  remain  within  the    
therapeutic  range  throughout  the  dosing  interval (63).This  view  has, 
however, been  challenged  by  observation  that  once-daily  
adminstration  of  artemisinin  derivatives, which  have  elimination  half  
lives  of <1 hour, is  not  associated  with  inferior  immediate  responses  
compared  to  more  ferequent  adminstration (63). 
             These  findings  are  consistent  with  our  study, however, this  comparison  
should  be  taken  cautiously; firstly, the  difference  in  the  transmission  rate  in  
different  locations  should  be  noted, for  example, in  Kenya  anti  malarial  
treatment  failures  were  found  to  be 9.5% and  34.5%  in  two  different  areas  at  
the  same  time. The  difference  was  attributed  to  the  variation  in  the  endemicity, 
hence  the  greater  drug  selection  preassure (64). Secondly  in  this  study  quinine  
was  assessed  in  all  age  groups  while  in  Guinea-Bissau  quinine  was  assessed  in  
children  who  are  more  likely  to  have  greater  parasite  resistance  to  antimalarials  
 49
than  the  other  groups (65). Thirdly, in  this  study  quinine  was  used  for  the  
treatment  of  chloroquine  resistant  falciparum  malaria,  whereas  in  the  previous  
study  patients  were  excluded  if  chloroquine  was  used. However, antagonism  
between  chloroquine  and quinine  was  previously  postulated (66,63). 
             Christophe  et al.  compared  the  efficacy  of  three  and  seven  days  oral  
regimen  of  quinine in  treatment  of  uncomplicated  falciparum  malaria  in  
Senegal.  
The  probability  of  being  free  of  parasiitaemia  was  higher  among  the  
older  children  regardless  of  the  treatment  group  increasing  by  a factor  of 1.6  
per  year  of  age  indicating  the  impact  of  immunity  on  parasitological  clearance  
time. Parasitaemia  detected  on  day  28  or  before  was 48% in  group 1 and  47%  in  
group 2 (67). 
            In  this  study  the  duration  of  the  treatment  was  different  
between  the  two   groups, but  the  total  daily  dose  of  quinine  was  
equal, however, in  our  study  the  duration  of  the  treatment  was  equal 
in  all  the  groups, but  the  total  daily  dose  was  different. The 
percentage of parasitaemia  detected  during  the  follow  up  period  in  
each  group  in  this  study  was  higher  than  that  in  our  study.  
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            Kofoed   et al. compared  the  effectiveness  of  three  regimens  of  
quinine  in  treatment  of  children  with  P. falciparum  malaria  in  Ginea-
Bissau. They  divided  the children  3 groups, treated for 3,5 and 7 days 
and received equal doses of quinine.    
          During the follow up period, the lowest percentage of children who 
had parasitaemia was detected in the 7 day treatment group(68) . Again 
this study demonstrates the influence of the length of quinine treatment 
period on recrudescence and re – infection rates.  
               Kofoed  and  colleagues  compared  different  doses  of  quinine  
for  treatment  of  falciparum  malaria  in  3  treatment  groups  of  
children treated for 7 days in  Guinea-Bissau.  The lowest percentage of 
children  who  have  parasitaemia  was  found  in  the  group  which  was 
treated by the highest daily dose of quinine (69). This clearly 
demonstrated the importance of the quinine dose as well as duration of 
the  treatment  in  treatment  of  falciparum malaria.        
              Studies invitro using  continuous culture of P.falciparum of the 
parasite population survives exposure to extremely high quinine 
concentration for up to 96 hours, while at low concentration of quinine 
similar to those obtained invivo, no live parasites were seen following 
168 hors of exposure, indicating that the period of treatment is very 
important (70). 
The  reduced  quinine  dose  in  this  study  was  found  effective  
in  clearing  parasitaemia  without  any  significant  difference  in  
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reappearing  of  parasitaemia. Natural  protective  immunity  may  have  
been  responsible  for  the  absence  of  a difference  between  the  
treatment  groups. Quinine is the second most prescribed ant-malarial 
drug in Sudan (71) , and  the  wide –spread  use  of  insufficient  dosage  
is  likely  to  enhance the development  of black  water  fever  and  
quinine –resistant  plasmodium  falciparum  strains, which  have  already  
been  reported  in  some  african  countries (72).. A previous  study  
carried  in  the  same  area – New  Halfa- showed  that  9.6% of  the  
patients  infected  with    plasmodium  falciparum  were  resistant  to  
quinine (9) .  
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Conclusion 
 
         In conclusion, a single daily dose with 15 mg quinine/kg.  for  7 days can be  
used   in  treatment of  chloroquine    resistant   falciparum  malaria in Sudan. We 
believe that this recommendation is valid for all age groups and probably also for 
other parts of Africa where quinine resistance is not suspected. 
Giving a single dose of 15mg.quinine/kg. for  7 days did not 
increase the level of severe adverse  drug  effects significantly although 
the risk should be considered  in future studies.  
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Recommendations 
 
  According  to  the  results  of  this  study,  I  recommend  the  use  
of  single  daily  dose  of  15 mg. quinine/kg.  for  7 days  for  treatment  
of  chloroquine  resistant  falciparum  malaria  in  Sudan. 
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Questionnaire 
Date: ………………………………………………………………… 
Name: ………………………………………………………………. 
Age: ………………………………………………………………… 
Sex: …………………………………………………………………. 
Address: …………………………………………………………….. 
Nearest  person  to  contact: …………………………………………. 
Last  dose  of  chloroquine: …………………………………………. 
Symptom: 
Fever     yes   no 
Headache    yes   no 
Vomiting    yes   no 
Nausea    yes   no 
Sweating    yes   no 
Chills     yes   no 
Backache    yes   no 
Diarrhoea    yes   no 
Abdominal   pain   yes   no 
Itching    yes   no 
Cough    yes   no 
Insomnia     yes   no 
Others    yes   no 
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Examination: 
Weight: …………………………………………………… 
Temperature: …………………………………………….. 
Pulse: …………………………………………………….. 
Blood  pressure: …………………………………………. 
Respiratory  rate: ………………………………………… 
Pallor: …………………………………………………… 
Jaundice: ………………………………………………… 
CVS: …………………………………………………….. 
Chest: ……………………………………………………. 
Abdomen: 
- Liver: ……………………………………… 
- Spleen: ……………………………………. 
Investigations: 
BFFM: ……………………………………………. 
Hb: ………………………………………………… 
Parasite  count: ……………………………………. 
Treatment: 
Quinine 
Dose:…………………………………………………… 
Oral: ………………………………………………….. 
Intravenous: …………………………………………… 
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Follow up chart: 
days 
Variable 
1 2 3 4 5 6 7 14 21 28 
Headache 
Vomiting           
Abd. Pain           
Backache           
Insomnia           
Giddiness           
Itching           
Tinnitus           
Temp.           
Liver           
Spleen           
BFFM           
Parasitaemia           
 
Temperature  clearance  time: ……………………………………. 
Parasite  clearance  time: ………………………………………….. 
 
